Oculus Innovative Sciences to Present at Biotech Showcase 2012 in San Francisco

PETALUMA, Calif., Dec. 29, 2011 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) today announced that the company's president and founder, Hoji Alimi, will present at Biotech Showcase 2012. The presentation includes an update on product launches scheduled in Q1 calendar year 2012 by partners Quinnova Pharmaceuticals (Amneal Pharmaceutical alliance member) and Eloquest Healthcare (Ferndale Laboratories subsidiary). The presentation is scheduled at 5:00 pm on Monday, January 9, 2012 at the Parc 55 Wyndham in San Francisco.

Quinnova Pharmaceuticals, which licensed the U.S. and Canadian rights to the Microcyn-based dermatology atopic dermatitis hydrogel is on track to launch its product next quarter. Eloquest Healthcare also plans to introduce a family of prescription wound care products under a private label. The product introduction targets the U.S. hospital market.  

Oculus most recently also raised approximately two million dollars. The investors included both existing as well as new institutions focused on the company's growth potential. The company plans to allocate a portion of these funds to further several product development projects that can be commercialized by partners.

Management anticipates there will be no material impact to its operating expenses and revenue, and thus is maintaining its previously provided guidance.

About Oculus Innovative Sciences

Oculus Innovative Sciences is a commercial healthcare company that designs, produces and markets innovative, safe and effective healthcare products. Oculus is pioneering innovative solutions in multiple markets including dermatology, oral care, surgical, wound care, animal healthcare and others, and has commercialized products in the United States, Europe, India, China and Mexico and select Middle East countries. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. More information can be found at www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the Company's commercial and technology progress and future financial performance. These forward-looking statements are identified by the use of words such as "launch," "plans," and "anticipates," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the annual report on Form 10-K for the year ended March 31, 2011. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements except as required by law.

Oculus and Microcyn are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

CONTACT: Oculus Innovative Sciences, Inc.
         Dan McFadden
         Director of Marketing/Communications
         (425) 753-2105
         dmcfadden@oculusis.com

Released December 29, 2011